Results of the Phase 2 ALPACA trial with the siRNA, lepodisiran, and the Phase 2 KRAKEN trial with the small molecule, muvalaplin, offer promising insights into the potential of these novel agents in the management of patients with elevated Lp(a) at increased risk of cardiovascular disease, as Professor Steve Nissen, Cleveland Clinic, Ohio, USA, reports.
Please login or create a FREE account to view this content
Educational Partners of the 2nd Closed Scientific Expert Meeting of the Editorial Board
Principal partners:
Guest partners:
